Alternative signaling pathways as potential therapeutic targets for overcoming EGFR and c-Met inhibitor resistance in non-small cell lung cancer
about
Mechanism of Resistance and Novel Targets Mediating Resistance to EGFR and c-Met Tyrosine Kinase Inhibitors in Non-Small Cell Lung CancerDown-regulation of miR-214 reverses erlotinib resistance in non-small-cell lung cancer through up-regulating LHX6 expression.Emerging molecular targets in oncology: clinical potential of MET/hepatocyte growth-factor inhibitors.Synthetic lethal screening reveals FGFR as one of the combinatorial targets to overcome resistance to Met-targeted therapyOverexpression of PI3K p110α contributes to acquired resistance to MET inhibitor, in MET-amplified SNU-5 gastric xenografts.Clinical Challenges to Current Molecularly Targeted Therapies in Lung CancerTargeting the MET pathway for potential treatment of NSCLC.Mechanism of c-Met and EGFR tyrosine kinase inhibitor resistance through epithelial mesenchymal transition in non-small cell lung cancer.HDAC-inhibition counteracts everolimus resistance in renal cell carcinoma in vitro by diminishing cdk2 and cyclin A.Targeting c-Met in melanoma: mechanism of resistance and efficacy of novel combinatorial inhibitor therapy.Wnt inhibitor XAV939 suppresses the viability of small cell lung cancer NCI-H446 cells and induces apoptosis.Synergistic effect of targeting dishevelled-3 and the epidermal growth factor receptor-tyrosine kinase inhibitor on mesothelioma cells in vitro.Comparison of EMT mediated tyrosine kinase inhibitor resistance in NSCLC.c-Met and Other Cell Surface Molecules: Interaction, Activation and Functional Consequences.
P2860
Q28547446-90BB73CF-B6A9-45C5-A5B9-05CE2566BA91Q33677872-C2765289-7485-4AE5-9394-38E4E08EF728Q33769437-5845FC4E-6903-40BC-AF46-8CACF98F0E93Q35129076-58070445-1FDA-4F15-B87C-46CFEC4C756AQ36213128-034199F7-446D-455F-A7A6-85DFD456772BQ36972377-5330EBDF-16F3-4059-81DB-CE49F13C5C0DQ38297235-79459C28-EBB8-49F6-9FB4-A278C8045622Q38758979-464AA7BF-8A09-489E-8B87-7F70B418EACEQ38984146-D7D27DB8-9A2A-4B8E-9459-D022D735E70CQ38986202-1A066C3B-A518-4F53-B89D-936A266536D4Q48533288-38EF262C-2B45-42B8-B8BF-85F41A36AAEDQ49387613-D1047249-46C8-4646-BDBE-B3ECA6BE0711Q50033862-BA6AD052-5B76-4FF7-B1F2-726813F58469Q50985108-5847483D-7A3F-44C0-AF8D-8C885738FD89
P2860
Alternative signaling pathways as potential therapeutic targets for overcoming EGFR and c-Met inhibitor resistance in non-small cell lung cancer
description
2013 nî lūn-bûn
@nan
2013 թուականին հրատարակուած գիտական յօդուած
@hyw
2013 թվականին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Alternative signaling pathways ...... in non-small cell lung cancer
@ast
Alternative signaling pathways ...... in non-small cell lung cancer
@en
Alternative signaling pathways ...... in non-small cell lung cancer
@nl
type
label
Alternative signaling pathways ...... in non-small cell lung cancer
@ast
Alternative signaling pathways ...... in non-small cell lung cancer
@en
Alternative signaling pathways ...... in non-small cell lung cancer
@nl
prefLabel
Alternative signaling pathways ...... in non-small cell lung cancer
@ast
Alternative signaling pathways ...... in non-small cell lung cancer
@en
Alternative signaling pathways ...... in non-small cell lung cancer
@nl
P2093
P2860
P1433
P1476
Alternative signaling pathways ...... in non-small cell lung cancer
@en
P2093
David N Moravec
Gregory M Botting
Jason T Fong
Marie Nlend
Neelu Puri
Ryan J Jacobs
Srijayaprakash B Uppada
P2860
P304
P356
10.1371/JOURNAL.PONE.0078398
P407
P577
2013-01-01T00:00:00Z